Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 4,000 Shares

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Theravance Biopharma Price Performance

Shares of TBPH stock opened at $9.68 on Thursday. The company’s fifty day simple moving average is $8.32 and its two-hundred day simple moving average is $8.68. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $11.71. The stock has a market capitalization of $473.56 million, a price-to-earnings ratio of -9.58 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The business had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same period in the previous year, the firm earned ($0.17) EPS. Equities research analysts anticipate that Theravance Biopharma, Inc. will post -1.04 EPS for the current year.

Analysts Set New Price Targets

TBPH has been the topic of a number of research reports. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. TD Cowen lowered their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Finally, Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $13.75.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Theravance Biopharma by 29.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,978 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 3,827 shares during the period. BNP Paribas Financial Markets grew its position in shares of Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after purchasing an additional 143,781 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Theravance Biopharma during the 3rd quarter valued at $60,000. Algert Global LLC purchased a new position in shares of Theravance Biopharma during the 3rd quarter valued at $851,000. Finally, GSA Capital Partners LLP grew its position in shares of Theravance Biopharma by 12.6% during the 3rd quarter. GSA Capital Partners LLP now owns 229,780 shares of the biopharmaceutical company’s stock valued at $1,852,000 after purchasing an additional 25,691 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.